Genetic changes such as amplifying the Epidermal Growth Factor Receptor (EGFR), Platelet-Derived Growth Factor Receptor Alpha (PDGFRA), and Cyclin-Dependent Kinases 4 and 6 (CDK4/6), deletions or inactivating mutations of TP53, Phosphatase and Tensin Homolog (PTEN), Neurofibromin 1 (NF1), and CDKN2A/B could induce the variability of tumors among GBM patients [11]. The gene discussed is PTEN; the disease is glioblastoma.